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Peripheral benzodiazepine receptor (PBR) is a multifunctional protein mainly found on the outer
mitochondrial membrane. PBR expression is increased by tumor necrosis factor-a (TNF-a) in endo-
thelial cells. Adenoviral overexpression of PBR inhibits monocyte adhesion, VCAM-1, and ICAM-1
expression in TNF-a-activated endothelial cells. Rotenone, cyclosporine A, and bongkrekic acid sup-
press TNF-a-induced VCAM-1 expression. Overexpression of PBR inhibits voltage-dependent anion
channel-1 (VDAC-1) expression and the silencing of PBR increases VDAC-1 expression in endothelial
cells. Moreover, TNF-a-induced VCAM-1 expression is suppressed by VDAC-1 gene silencing. PBR
overexpression signiﬁcantly decreases TNF-a-induced mitochondrial reactive oxygen species and
MnSOD expression. These results suggest that PBR can inhibit endothelial activation and this action
is related to the inhibition of mitochondrial ROS and/or VDAC-1 expression in endothelial cells.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Vascular inﬂammation is the primary cause of cardiovascular
diseases, such as atherosclerosis. The expression of vascular adhe-
sion molecules and monocyte adhesion to the vascular endothelial
cells are crucial events in the pathological process of endothelial
activation [1].
The peripheral benzodiazepine receptor (PBR) was shown to be
a benzodiazepine binding site present outside the central nervous
system, which is in contrast to central-type benzodiazepine recep-
tors [2]. The 18-kD PBR is a highly hydrophobic protein primarily
localized on the outer mitochondrial membrane [3], where it asso-
ciates with the voltage-dependent anion channel (VDAC-1) and the
nucleotide adenine transporter to form the mitochondrial
permeability transition pore [4]. Putative PBR functions include
regulation of steroidogenesis, apoptosis, cell proliferation, the
mitochondrial membrane potential, and the mitochondrial respira-
tory chain [5]. PBR knockout in mice was shown to be lethal in the
embryonic stage, suggesting that PBR may be involved in severalchemical Societies. Published by E
ysiology, School of Medicine,
Jung-gu, Daejeon 301-747,critical functions [6]. A high expression of PBR has been observed
in steroid-producing tissues as well as in the heart, liver, kidney,
and blood cells [7]. However, PBR is ubiquitous throughout the
body and is also expressed in vascular endothelial cells [8]. There-
fore, PBR may be involved in several aspects of cardiovascular
disease [7].
PBR expression levels have been correlated with certain disease
states. PBR expression was increased in the arterial plaque of pa-
tients with atherosclerosis [9] and inﬂammation [10], suggesting
that a high expression of PBR is strongly correlated with tissue
inﬂammation. Furthermore, PBR protein expression and mRNA lev-
els were found to be up-regulated by cytokines in Leydig cells [11],
human pancreatic islets [12] and microglia [13,14]. There have also
been some studies showing PBR ligands reduced carrageenan-in-
duced inﬂammation and vascular inﬂammation [8,15,16]. How-
ever, the putative role of PBR has been deduced from based on
the biological effect of its synthetic ligands and the results from
these studies were relatively inconsistent [17].
Since previous reports showed that PBR was correlated with
inﬂammation, we hypothesized that the PBR might be involved in
endogenous vascular endothelial protection. In the present study,
we investigated the direct role of PBR overexpression using adeno-
viral gene transfer in vascular endothelial activation, primarily, in
regards to mitochondrial function in vascular endothelial cells.lsevier B.V. All rights reserved.
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2.1. Cell culture and drugs
Human umbilical vein endothelial cells (HUVECs) were pur-
chased from Clonetics (Cambrex Bio Science, MD, USA), and were
grown and maintained in endothelial growth medium. Cells were
used between passages 3 and 6. U937 cell lines were obtained from
American type culture collection (Manassas, VA, USA). Anti-VCAM-
1 (sc-8304), anti-ICAM-1 (sc-7891), anti-Hsp60 (sc-13115), and
anti-b-actin were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Anti-MnSOD (Stressgen, SOD-110), anti-VDAC-1
(Cell Signaling (#4866), and anti-PBR (Novus Biologicals, NB100-
41398) were also used for analysis. HRP-labeled anti-rabbit anti-
bodies and phorbol 12-myristate 13-acetate (PMA) were obtained
from Calbiochem (La Jolla, CA). Human TNF-a, rotenone, cyclospor-
ine A, and anti-Flag (F3165) were purchased from Sigma (St. Louis,
MO. USA). Bongkrekic acid was purchased from Enzo Life Sciences
(Farmingdale, NY, USA). Cell viability was measured using the
automated mammalian cell counter (ADAM-MC, Digital Bio, Korea)
which analyzed the cells stained with propidium iodide.
2.2. The adenoviral vector construction of human PBR
The overexpression of human PBR (hPBR) in endothelial cells
was accomplished using a replication-incompetent (E1, E3 deleted)
adenovirus created by the Viralpower adenovirus expression sys-
tem (Invitrogen, Carlsbad, CA, USA). Brieﬂy, human PBR (hPBR)
was isolated from PBR cDNA in pEGFP-N1 (Clontech, Mountain
View, CA, USA), which was matched with Genbank accession num-
ber BC001110 [16] using the following primers with the restriction
enzyme linkers, sense primer: 50-AAA GGA TCC ATG GCC CCG CCC
TGG-30 (containing an BamHI restriction site), antisense primer: 50-
AAA CTC GAG TCA CTC TGG CAG CCG-30 (containing XhoI restric-
tion site). After digestion with BamHI and XhoI, full length hPBR
constructs were cloned into the pENTR-CMV-FLAG vector, which
contains attL sites for site-speciﬁc recombination with a Gateway
destination vector and entry vector (Invitrogen, Carlsbad, CA,
USA) which has been described previously [18].
2.3. Monocyte–endothelial cell adhesion assay
Monocyte–endothelial cell adhesion assay was performed as
described previously [19,20]. U937 cells were ﬂuorescently labeled
with 20,70-bis-(2-carboxyethyl)-5-(and-6)-carboxy-ﬂuorescein
acetoxymethyl ester (BCECF-AM) for the quantitative adhesion as-
say. The U937 cells were ﬂuorescently labeled by incubating the
cells (1  107 cells/ml) with 1 lM BCECF-AM in RPMI-1640 med-
ium for 30 min at 37 C and 5% CO2. Monocyte adhesion was
quantiﬁed by measuring ﬂuorescence (excitation – 485 nm and
emission – 535 nm).
2.4. Western blot analysis
For Western blot analysis, HUVECs were harvested with 100 ll
of lysis buffer containing 20 mM Tris–Cl, pH 7.5, 100 mM NaCl,
2 mM EDTA, 2 mM EGTA, 1 mM Na3VO3, 1 mM b-glycerophos-
phate, 4 mM Na pyrophosphate, 5 mM NaF, and 1% Triton X-100,
and protease inhibitor cocktail. Proteins (30 lg) were separated
by 12% SDS–PAGE and electrotransfered onto polyvinylidene ﬂuo-
ride (PVDF) membranes. After blocking with 5% skimmilk for 1 h at
room temperature, blots were incubated overnight at 4 C with
speciﬁc primary antibodies (1:1000 dilutions for anti-MnSOD,
VCAM-1, ICAM-1, VDAC-1, 1:2000 dilution for anti-PBR, 1:5000
dilution for anti-Flag) and subsequently detected with horseradishperoxidase (HRP)-conjugated secondary antibodies. Blots were
developed for visualization using an enhanced chemiluminescence
detection kit (Pierce, USA).
2.5. siRNA preparation and transfection
Small interfering RNAs (siRNAs) to human VDAC-1 and PBR,
consisting of 21 nucleotides, were synthesized from Bioneer Co.
(Daejeon, Korea). The GeneBank accession number for human
VDAC-1 and PBR were NM 003374 and NM 000714 respectively.
siRNA duplexes with the following gene-speciﬁc sense sequences
were used; VDAC-1 siRNA targeting human VDAC-1: 50-CGU CUA
UAA GCU UGG AAG UdTdt-30. PBR siRNA targeting human PBR:
50-CGU AUG GCG GGA CAA CCA UdTdT-30. The following negative
control siRNA (Bioneer Co, Korea) was used; negative control oligo-
nucleotide template: 50-CCU ACG CCA CCA AUU UCG UdTdT-30. A
single transfection of 10–100 nM siRNA duplexes was performed
using the Lipofectamine™ 2000 reagent (Invitrogen, San Diego,
CA). Cells were incubated at 37 C in a CO2 incubator for 72 h for
gene knockdown.
2.6. Fluorescence detection of mitochondrial ROS
The effects of PBR on mitochondrial superoxide production in
endothelial cells was assessed using MitoSox red (Invitrogen,
Carlsbad, CA), a mitochondrion-speciﬁc hydroethidine-derivative
ﬂuorescent dye that undergoes oxidation to form the DNA-binding
red ﬂuorophore ethidium bromide [21]. HUVECs were incubated
with MitoSox red (5 lM) for 10 min in a CO2 incubator. After expo-
sure to TNF-a for 18 h, cells were washed with PBS and the ﬂuores-
cent signals were analyzed using a ﬂuocytometer. The data are
presented as fold changes in the mean intensity of MitoSox ﬂuores-
cence when compared with the respective controls. Fluorescence
images were obtained by ﬂuorescence microscopy (Zeiss, Carl Zeiss
Inc, Thornwood, NY).
2.7. Statistical analysis
Values are expressed as the mean ± S.E.M. Statistical evalua-
tions were performed using one-way analysis of variance followed
by Dunnett’s test, with P < 0.05 considered signiﬁcant.
3. Results
3.1. PBR was up-regulated by the exposure of inﬂammatory cytokines
To investigate whether endogenous PBR expression is changed
by exposure to inﬂammatory cytokines, such as TNF-a, we investi-
gated the changes in PBR and VCAM-1 expression in endothelial
cells exposed to TNF-a for 3–18 h. In this experiment, PMA was
used as positive control since PKC agonists have been known to in-
crease PBR promotor activity [22]. As shown in Fig. 1, the exposure
of TNF-a increased PBR expression as well as VCAM-1 expression
in endothelial cells. PBR expression reached a maximum at 12 h,
which corresponded to the maximum expression of VCAM-1. This
data suggested that PBR expression levels were correlated with
endothelial cell activation.
3.2. Overexpression of PBR inhibits TNF-a-induced endothelial
activations: VCAM-1, ICAM-1 expression and monocyte adhesion
To determine if PBR regulates TNF-a-induced adhesion mole-
cule expression, we examined the effect of PBR overexpression
on TNF-a-induced VCAM-1 and ICAM-1 expression. As shown in
Fig. 2A, VCAM-1 and ICAM-1 was not detected in un-stimulated
VCAM-1
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Fig. 1. TNF-a increased PBR and VCAM-1 expression in endothelial cells. (A) Endothelial cells were exposed to TNF-a (15 ng/ml for 3–18 h) or PMA (100 nM for 18 h),
harvested and transferred for Western blot analysis as described in Section 2. Expression levels are represented as fold values of basal PBR expression levels. Each bar shows
mean ± S.E. (n = 4). ⁄P < 0.05 vs basal.
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Fig. 2. PBR overexpression inhibited TNF-a-induced adhesion molecules and monocyte adhesion in endothelial cells. A. PBR overexpression inhibited TNF-a-induced vascular
cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). Total adenoviral infection was 100 MOI, which was balanced with Adbgal. b-actin was
used as loading control. (B) PBR overexpression inhibited TNF-a-induced monocyte adhesion on endothelial cells. Monocyte adhesion was assessed using the monocyte–
endothelial cell adhesion assay described in Section 2. (B) Typical monocyte adhesion image, (C) Densitometric data for Fig 2B. Total adenoviral infection was 100 MOI, which
was balanced with Adbgal. Expression levels are represented as % densitometic value of monocyte adhesion induced by TNF-a. Each bar shows mean ± S.E. (n = 6). ⁄P < 0.05 vs
TNF-a alone.
H.K. Joo et al. / FEBS Letters 586 (2012) 1349–1355 1351endothelial cells, but treatment with TNF-a resulted in a marked
increase in VCAM-1 and ICAM-1 expression. HUVEC cells were in-
fected with AdPBR at various MOI for 24 h and PBR overexpression
was conﬁrmed by Western blot analysis using the Anti-FLAG anti-
body. Adenoviral overexpression of PBR inhibited TNF-a-induced
VCAM-1 and ICAM-1 expression in a dose dependent manner.
Since PBR inhibited the expression of adhesion molecules in TNF-
a-stimulated endothelial cells, the effect of PBR overexpression
on TNF-a-induced monocyte adhesion was investigated. As shown
in Fig. 2B, un-stimulated HUVECs displayed minimal monocyte
adhesion, but monocyte adhesion was increased when HUVECs
were treated with TNF-a. In contrast, PBR overexpressing in HU-
VECs signiﬁcantly attenuated monocyte adhesion induced by
TNF-a in a dose dependent manner at AdPBR MOI values ranging
from 10–100 MOI. These ﬁndings indicate that PBR overexpression
selectively prevents endothelium-monocyte adhesion stimulated
by TNF-a. For quantitative analysis of monocyte adhesion, the data
was plotted as a percentage of adhesion in TNF-a alone (Fig. 2C).3.3. Mitochondrial ROS inhibitor inhibited TNF-a-induced VCAM-1
expression
Mitochondrial ROS are involved in cellular signaling through
different pathways. To examine the involvement of mitochondrial
ROS in endothelial cells activation, we investigated the effect of
rotenone, a mitochondrial complex I inhibitor, on TNF-a-induced
VCAM-1 expression. As shown in Fig. 3A, pretreatment with rote-
none (5 lM) signiﬁcantly inhibited TNF-a-induced VCAM-1
expression. This data suggested that mitochondrial ROS governs
VCAM-1 expression in response to TNF-a in endothelial cells.
Cyclosporin A and bongkrekic acid inhibit the mitochondrial
permeability transition pore (MPTP) by binding to matrix cyclophi-
lin (CyP)-D, a peptidyl-prolyl cis–trans isomerase and by inhibiting
of adenine nucleotide translocase [23–25]. We investigated
whether TNF-a-induced VCAM-1 expression is affected by MPTP
inhibitors. As shown in Fig. 3C and E, pretreatment with cyclospor-
ine A or bongkrekic acid itself did not affect VCAM-1 expression.
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Fig. 3. Effect of rotenone, cyclosporine A and bongkrekic acid on TNF-a-induced VCAM-1 expression in endothelial cells. (A) Rotenone inhibited TNF-a-induced VCAM-1
expression in a dose-dependent manner (1–5 lM). (C) Cyclosporin A (CS) inhibited TNF-a-induced VCAM-1 expression in a dose-dependent manner (1–10 lM). (E)
Bongkrekic acid (BA) inhibited TNF-a-induced VCAM-1 expression in a dose-dependent manner (1–10 lM). (B,D,F) Densitometric data for Fig. 3A, C and E. Each bar shows the
mean ± S.E. (n = 5). ⁄P < 0.05. Each data was represented as % densitometric value of VCAM-1 expression induced by TNF-a (15 ng/ml). Each bar shows the mean ± S.E. (n = 5).
⁄P < 0.05 vs TNF-a alone.
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inhibited by cyclosporin A or bongkrekic acid in a dose dependent
manner (1–10 lM), suggesting that the closing of MPTP inhibited
TNF-a-induced VCAM-1 expression in endothelial cells. For quan-
titative analysis, the data were plotted as a percentage of VCAM-
1 expression (Fig. 3D and F).
3.4. PBR regulated VDAC-1 expression in endothelial cells
Having established that PBR inhibited TNF-a-induced adhesion
molecule expression and monocyte adhesion, we next examined
how PBR inhibited endothelial cells activation. Voltage-dependent
anion-selective channel protein 1 (VDAC-1) overexpression trig-
gers MPTP opening via an increase in ROS, whereas silencingVDAC-1 expression inhibits MPTP [26]. Therefore, we investigated
the effect of PBR overexpression on VDAC-1 expression in endothe-
lial cells. As shown in Fig. 4A, PBR overexpression markedly inhib-
ited VDAC-1 expression in endothelial cells. In contrast, Hsp60
expression as a mitochondria marker was not changed by PBR
overexpression. To conﬁrm the role of endogenous PBR on VDAC-
1 expression, the effect of siRNA for PBR on VDAC-1 expression
in HUVECs was examined. As shown in Fig. 4B, gene silencing of
PBR using siRNA for PBR increased VDAC-1 expression.
We next investigated whether the silencing of VDAC-1 affected
TNF-a-induced VCAM-1 expression. As shown in Fig. 4C, VDAC-1
expression was increased by exposure to different concentrations
of TNF-a (1–15 ng/ml). Incubation of siRNA for VDAC-1 over 72 h
completely suppressed endogenous VDAC-1 expression in
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Fig. 4. PBR regulated VDAC-1 expression in endothelial cells. (A) PBR overexpression inhibited VDAC-1 expression. The total adenoviral infection was 100 MOI, which was
balanced with Adbgal. Hsp60 was used as mitochondrial protein marker. (B) Effect of siRNA for PBR on VDAC-1 expression. (C) Effect of siRNA for VDAC-1 on TNF-a increased
VCAM-1 expression. Seventy-two hours after transfection with the siRNA for PBR and VDAC-1, PBR and VDAC-1 expression in endothelial cells was markedly decreased.
Scrambled siRNA for used as a control for siRNA treatment. D. Densitometric data for Fig. 4C. Each bar shows the mean ± S.E. (n = 3). ⁄P < 0.05 vs scramble siRNA.
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was suppressed in VDAC-1 siRNA-transfected cells when compared
with that of cells transfected with scrambled siRNA (Fig. 4D).
3.5. PBR reduced TNF-a-induced mitochondrial ROS and MnSOD
expression
We investigated whether PBR overexpression affected TNF-a-
induced mitochondrial ROS production. Mitochondrial superoxide
production in endothelial cells was assessed using MitoSox red, a
mitochondrion-speciﬁc hydroethidine-derivative ﬂuorescent dye.
After exposing AdPBR-overexpressed HUVECs to TNF-a for 18 h,
the ﬂuorescent signals were analyzed. As shown in Fig. 5A, TNF-a
increased mitochondrial ROS ﬂuorescent signals in Adbgal-control
cells; however, TNF-a-induced mitochondrial ROS production was
blunted in AdPBR-overexpressed cells, which suggests that PBR
inhibits ROS production.
The anti-oxidant enzyme levels of manganese superoxide dis-
mutase (MnSOD) in the mitochondria are dramatically elevated
in response to stimulation with TNF-a [27]. Therefore, we investi-
gated the effect of PBR overexpression on MnSOD expression in
endothelial cells. As shown in Fig. 5C, TNF-a-induced MnSOD
expression was decreased by the overexpression of PBR in a dose
dependent manner. These results suggest that the reduced ROS
production by PBR resulted in decreased MnSOD expression in
endothelial cells.
4. Discussion
Despite the large number of studies describing PBR protein lev-
els in various tissues, little is known about the mechanism under-
ling its regulation in endothelial cells. The present study has been
demonstrated that PBR regulates endothelial cell activation. The
anti-inﬂammatory action of PBR might be mediated by inhibiting
mitochondrial ROS and VDAC-1 expression.
PBR is an 18 kDa protein that has been implicated in numerous
cell functions and is expressed in endothelial cells [16]. Our data
showed that exposure to TNF-a increased PBR expression as wellas VCAM-1 expression in endothelial cells. This data suggested that
PBR expression levels were correlated with endothelial cell activa-
tion. Also, TNF-a seems to be the key activator of PBR protein
expression.
TNF-a is known to cause monocyte adhesion, adhesion mole-
cules and marked oxidative stress in endothelial cells [19]. To
investigate the role of PBR in endothelial cell activation, TNF-a
was used to induce endothelial cell activation as previously re-
ported [19,28]. Moreover, adhesion molecules, such as VCAM-1
or ICAM-1, mediate leukocyte–endothelial cell adhesion and signal
transduction, and it may play a role in the development of vascular
inﬂammation or atherosclerosis [19]. Therefore, because monocyte
adhesion may play an important role in the pathophysiological re-
sponse to vascular inﬂammation, we tested whether overexpres-
sion of PBR had an anti-adhesive effect on the adhesion of
monocytes to human endothelial cells. Overexpression of PBR
inhibited TNF-a-induced VCAM-1 and ICAM-1 expression and
monocyte adhesion in endothelial cells. Adenoviral overexpression
of PBR did not affect the mitochondrial integrity which was as-
sessed by Mitotracker staining and the endothelial cell viability
(see Supplementary Figures). Therefore, our data clearly showed
that PBR is involved in anti-adhesive action via suppression of
adhesive molecule expression in endothelial cells.
In the present study, TNF-a-induced VCAM-1 expression was
signiﬁcantly inhibited by rotenone, a mitochondrial complex I
inhibitor, and cyclosporin A or bongkrekic acid, a MPTP inhibitor.
These data suggested that the mitochondrial respiration and a
change in MPTP opening can modulate the inﬂammatory process
in response to cytokines, such as TNF-a, in endothelial cells. There-
fore, our data showed MPTP of mitochondria governed the expres-
sion of adhesion molecules in endothelial cells.
Voltage-dependent anion channel (VDAC-1) is the main chan-
nel of the mitochondrial outer membrane and has been proposed
to be part of the mitochondrial permeability transition pore
[29,30]. VDAC-1 overexpression triggers MPTP opening via an in-
crease in ROS and activation of p38. Conversely, silencing VDAC-1
expression inhibits the opening of MPTP caused by oxidative
stress [26]. Our data showed that VDAC-1 expression was
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Fig. 5. PBR overexpression inhibited TNF-a -induced mitochondrial superoxide production and manganese superoxide dismutase (MnSOD) expression in endothelial cells.
(A) Representative ﬂuorescent image showing endothelial cells stained with superoxide-sensitive MitoSox ﬂuorescent dye. (B) PBR overexpression inhibited TNF- a-induced
mitochondrial superoxide production. Each data was represented as an arbitrary value of ﬂuorescent intensity. Each bar showed mean ± S.E. (n = 5). ⁄P < 0.05. (C) PBR
overexpression inhibited TNF-a-induced MnSOD expression in a MOI dependent manner. Total adenoviral infection was 100 MOI, which was balanced with Adbgal. (D)
Densitometric data for Fig. 5C. Each bar shows the mean ± S.E. (n = 3). ⁄P < 0.05 vs TNF-a alone.
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gene silencing of PBR resulted in an increase in VDAC-1 expres-
sion in endothelial cells. This result suggests that mitochondrial
PBR suppressed VDAC-1 expression, which is involved in MPTP
opening. Gene silencing of VDAC-1 suppressed TNF-a-induced
VCAM-1 expression, suggested that mitochondrial VDAC-1 is in-
volved in TNF-a-induced inﬂammatory signaling in endothelial
cells.
In endothelial cells, TNF-a stimulated ROS production through
several mechanisms [31]. The potential implications of PBR in
VDAC-1 expression might be related to a decrease in mitochon-
drial ROS production. Increased mitochondrial ROS generation
can be associated with increased adhesion molecule expression
in cardiovascular disorders. Especially, mitochondrial dysfunction
may play an important role in the initiation and development of
atheriosclerosis [32]. Our data showed TNF-a-induced mitochon-
drial ROS production was signiﬁcantly inhibited by PBR overex-
pression. Manganese superoxide dismutase (MnSOD), which is
a vital anti-oxidant enzyme localized to the mitochondrial ma-
trix, catalyzes the dismutation of superoxide anions to hydrogen
peroxide. MnSOD, which was used as a marker of mitochondiral
oxidative stress, is dramatically elevated in response to stimula-
tion with TNF-a. It should be noted however, that PBR did not
up-regulate antioxidant enzymes such as MnSOD. On the con-
trary, it decreased the expression of MnSOD which was up-regu-
lated by superoxide. This result suggests that PBR decreases
mitochondrial ROS generation via MnSOD-independent mecha-
nism. However, it suggested that the reduced mitochondrial
ROS generation by PBR overexpression resulted in decreased
MnSOD expression.
Taken together, these ﬁndings indicate that PBR can inhibit
endothelial activation and this effect was related to its ability to in-
hibit VDAC-1 expression in endothelial cells. Moreover, our data
suggested a functional role of PBR in regulating of endothelial acti-
vation by modulating mitochondrial function.Acknowledgments
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